(0.01%) 5 517.50 points
(0.12%) 39 893 points
(0.05%) 19 760 points
(-0.04%) $81.60
(0.43%) $2.82
(-0.25%) $2 338.50
(0.12%) $29.56
(0.52%) $1 007.00
(0.10%) $0.932
(-0.10%) $10.52
(0.01%) $0.788
(-0.85%) $87.25
-10.14% $ 2.66
Live Chart Being Loaded With Signals
Taysha Gene Therapies, Inc., a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system...
Stats | |
---|---|
Dzisiejszy wolumen | 2.17M |
Średni wolumen | 2.22M |
Kapitalizacja rynkowa | 497.47M |
EPS | $-0.100 ( Q1 | 2024-05-14 ) |
Następna data zysków | ( $-0.100 ) 2024-08-12 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E |
-3.41 (Sector) 42.63 (Industry) 24.32 |
ATR14 | $0.00700 (0.26%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-05-29 | Stalfort John A Iii | Buy | 49 220 | Common Stock |
2024-05-29 | Stalfort John A Iii | Buy | 98 440 | Stock Option (right to buy) |
2024-05-29 | Long Alison S | Buy | 98 440 | Stock Option (right to buy) |
2024-05-29 | Long Alison S | Buy | 49 220 | Common Stock |
2024-05-29 | Donenberg Phillip B. | Buy | 49 220 | Common Stock |
INSIDER POWER |
---|
95.64 |
Last 98 transactions |
Buy: 30 046 285 | Sell: 943 112 |
Wolumen Korelacja
Taysha Gene Therapies, Korelacja
10 Najbardziej pozytywne korelacje | |
---|---|
MACK | 0.884 |
MEDP | 0.882 |
TRVI | 0.874 |
PLMR | 0.873 |
FPXI | 0.872 |
FCYIX | 0.862 |
PHO | 0.859 |
TRMB | 0.857 |
HTHT | 0.853 |
CGO | 0.853 |
10 Najbardziej negatywne korelacje | |
---|---|
SSRM | -0.872 |
CYAN | -0.871 |
LTRX | -0.865 |
WISA | -0.857 |
MFIN | -0.85 |
WTER | -0.846 |
VLCN | -0.845 |
SSP | -0.832 |
ROIC | -0.83 |
RAPT | -0.829 |
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
Taysha Gene Therapies, Korelacja - Waluta/Towar
Taysha Gene Therapies, Finanse
Annual | 2023 |
Przychody: | $15.45M |
Zysk brutto: | $14.08M (91.13 %) |
EPS: | $-0.960 |
FY | 2023 |
Przychody: | $15.45M |
Zysk brutto: | $14.08M (91.13 %) |
EPS: | $-0.960 |
FY | 2022 |
Przychody: | $2.50M |
Zysk brutto: | $15 000.00 (0.60 %) |
EPS: | $-3.86 |
FY | 2021 |
Przychody: | $0.00 |
Zysk brutto: | $0.00 (0.00 %) |
EPS: | $-4.64 |
Financial Reports:
No articles found.
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Taysha Gene Therapies,
Taysha Gene Therapies, Inc., a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN1 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 foe the treatment of for SLC13A5 Deficiency; and TSHA-101 for the treatment of GM2 gangliosidosis. Taysha Gene Therapies, Inc. has a strategic partnership with The University of Texas Southwestern Medical Center to develop and commercialize transformative gene therapy treatments. The company was incorporated in 2019 and is based in Dallas, Texas.
O Sygnały na żywo
Prezentowane na tej stronie sygnały na żywo pomagają określić, kiedy KUPIĆ lub SPRZEDAĆ BRAK DANYCH. Sygnały mogą mieć opóźnienie wynoszące nawet 1 minutę; jak wszystkie sygnały rynkowe, istnieje ryzyko błędu lub pomyłki.
Sygnały transakcyjne na żywo nie są ostateczne i getagraph.com nie ponosi odpowiedzialności za żadne działania podjęte na podstawie tych sygnałów, jak opisano w Warunkach Użytkowania. Sygnały opierają się na szerokim zakresie wskaźników analizy technicznej